OliX PharmaceuticalsInc (226950) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.16 Billion ≈ $-8.24 Million USD) by net assets (₩150.08 Billion ≈ $101.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OliX PharmaceuticalsInc (226950) balance sheet quality index to measure how much of total assets are equity-financed.
OliX PharmaceuticalsInc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how OliX PharmaceuticalsInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of OliX PharmaceuticalsInc to evaluate the quality of earnings relative to operating cash generation.
OliX PharmaceuticalsInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OliX PharmaceuticalsInc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangling Motors Corp Ltd
SHE:000550
|
0.015x |
|
Shilpa Medicare Limited
NSE:SHILPAMED
|
0.083x |
|
Shandong Sacred Sun Power Sources Co Ltd
SHE:002580
|
0.017x |
|
ROMANDE ENERGIE SA
SW:REHN
|
0.072x |
|
China Communications Services Corporation Limited
F:CMW
|
-0.012x |
|
Henan Thinker Automation
SHG:603508
|
0.027x |
|
Forbo Holding AG
SW:FORN
|
-0.024x |
|
ACV Auctions Inc.
NASDAQ:ACVA
|
0.024x |
Annual Cash Flow Conversion Efficiency for OliX PharmaceuticalsInc (2016–2025)
The table below shows the annual cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see OliX PharmaceuticalsInc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩150.08 Billion ≈ $101.71 Million |
₩-15.90 Billion ≈ $-10.78 Million |
-0.106x | +93.26% |
| 2024-12-31 | ₩17.85 Billion ≈ $12.10 Million |
₩-28.04 Billion ≈ $-19.01 Million |
-1.571x | -273.62% |
| 2023-12-31 | ₩50.34 Billion ≈ $34.11 Million |
₩-21.17 Billion ≈ $-14.35 Million |
-0.421x | +9.67% |
| 2022-12-31 | ₩65.91 Billion ≈ $44.66 Million |
₩-30.68 Billion ≈ $-20.79 Million |
-0.466x | +54.75% |
| 2021-12-31 | ₩18.52 Billion ≈ $12.55 Million |
₩-19.05 Billion ≈ $-12.91 Million |
-1.029x | -1139.29% |
| 2020-12-31 | ₩45.29 Billion ≈ $30.69 Million |
₩-3.76 Billion ≈ $-2.55 Million |
-0.083x | +67.67% |
| 2019-12-31 | ₩41.80 Billion ≈ $28.33 Million |
₩-10.73 Billion ≈ $-7.27 Million |
-0.257x | -68.76% |
| 2018-12-31 | ₩54.94 Billion ≈ $37.23 Million |
₩-8.36 Billion ≈ $-5.67 Million |
-0.152x | +40.64% |
| 2017-12-31 | ₩18.68 Billion ≈ $12.66 Million |
₩-4.79 Billion ≈ $-3.24 Million |
-0.256x | +6.67% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
₩-3.45 Billion ≈ $-2.34 Million |
-0.275x | -- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more